Research programme: late sodium current blockers - Gilead Sciences
Alternative Names: Late INALatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator CV Therapeutics
- Class Dihydropyridines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (PO)
- 31 Dec 2012 Gilead advances its late sodium channel inhibitor, designated GS 6615, into clinical development for Ischaemic heart disease and Arrhythmias
- 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences